Peak Inspiratory Flow Rates in Patients With COPD

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-31

Study Completion Date

2022-04-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recent studies have reported that some Chronic Obstructive Pulmonary Disease (COPD) patients may have a suboptimal ability to generate a sufficient inspiratory effort to achieve adequate lung delivery of inhaled medications through dry powder inhalers. Sparse data is available about the inspiratory capacity of these patients in the home setting, whether clinically stable or when experiencing worsened respiratory symptoms outside the acute care setting. This study is undertaken to better understand the proportion of patients with suboptimal peak inspiratory flow rate (sPIFR) measurements amongst COPD patients receiving dry powder inhaler(s) (DPI) in the ambulatory setting. Further, the study will characterize PIFR over time, the variability of PIFR measurements, and the associations with potential predictors (demographics, clinical, Patient-Reported Outcomes (PRO), body position, and device) as well as exacerbations frequency and change in PIFR around period of exacerbation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Optimizing Maintenance Therapy in COPD Patients

NCT04532853

COPD

COMPLETED

Nasal High Flow to Maintain the Benefits of Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease Patients

NCT03882372

Chronic Obstructive Pulmonary Disease

TERMINATED NA

Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations

NCT04360226

Chronic Obstructive Pulmonary Disease

COMPLETED

Effects of PEP on IC During IT in Patients With COPD

NCT03657082

Chronic Obstructive Pulmonary Disease

TERMINATED NA

Pilot Study of Physiological Effect of High-Flow Nasal Cannula on Respiratory Pattern and Work of Breathing

NCT02514798

COPD

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recent studies have reported that some COPD patients may have a suboptimal ability to generate a sufficient inspiratory effort to achieve adequate lung delivery of inhaled medications through dry powder inhalers. Sparse data is available about the inspiratory capacity of these patients in the home setting, whether clinically stable or when experiencing worsened respiratory symptoms outside the acute care setting. This study is undertaking this study to better understand the proportion of patients with suboptimal peak inspiratory flow rate (sPIFR) measurements amongst COPD patients receiving dry powder inhaler(s) (DPI) in the ambulatory setting. Further, the study will characterize PIFR over time, the variability of PIFR measurements, and the associations with potential predictors (demographics, clinical, PRO, body position, and device) as well as exacerbations frequency and change in PIFR around period of exacerbation. To complete these aims, 120 participants will be enrolled in a 6 month study to perform PIFR measurements and respiratory questionnaires at home.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Home PIFR monitoring

Measurement of PIFR using the InCheck Dial® device and quantification of respiratory symptoms and COPD exacerbations using standardized questionnaires in the patient's home setting and during research visits in the clinic setting

Group Type OTHER

Home PIFR monitoring with InCheck Dial

Intervention Type DEVICE

The In-Check G16 DIAL® (Alliance Tech Medical, Granbury TX) is a simple hand-held device that measures PIFR via a brief inspiratory maneuver.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Home PIFR monitoring with InCheck Dial

The In-Check G16 DIAL® (Alliance Tech Medical, Granbury TX) is a simple hand-held device that measures PIFR via a brief inspiratory maneuver.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 50 years-old
* Spirometry-confirmed diagnosis of COPD (FEV1/FVC \<0.70)
* Global initiative for Chronic Obstructive Lung Disease (GOLD) II-IV based on spirometry results
* COPD Assessment Test (CAT) score \> 10
* For high resistance DPI, baseline PIFR \< 90 L/min (InCheck DIAL®) and \>=30 L/min; for medium resistance DPI, PIFR ≤ 90 L/min (InCheck DIAL®) and \>=60 L/min. Handihaler is a high resistance DPI. Examples of medium resistance DPI: Anoro, Incruse, Breo Ellipta®, Advair® Diskus® DP or Wixela® Inhub®
* History of smoking tobacco products \> 10 pack years
* Prescribed at least one daily maintenance DPI with no change in prescription within the four weeks prior to the Enrollment Visit
* One or more exacerbations of COPD requiring systemic corticosteroids within last 2 years

Exclusion Criteria

* Inability to demonstrate proper technique for the InCheck DIAL® device
* Inability to achieve minimum PIFR for prescribed DPI(s) at screening/enrollment visit (\< 30 L/min for e.g., Handihaler® (High resistance DPI), \< 60 L/min for Ellipta® (Medium resistance DPI))
* Inability to perform spirometry to meet American Thoracic Society standards
* Neuromuscular disease associated with weakness
* Any condition that, in the opinion of the site investigator, would compromise the subject's ability to participate in the study.
* Pneumothorax within the past 4 weeks
* For those participants who will require spirometry (i.e., if they have not had it within the past 3 months): Participants who present with a myocardial infarction or eye, chest or abdominal surgery within six weeks of baseline can be rescreened after the six week window has passed

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No